肝硬化腹水合并低钠血症患者的临床治疗研究  

Study on clinical treatment of cirrhotic ascites complicated with hyponatremia patients

作　　者：姬群英[1] JI Qun-ying.(Department of Infectious Disease, Shandong Province Heze City Municipal Hospital, Heze 274000, Chin)

机构地区：[1]山东省菏泽市立医院传染科,274000

出　　处：《中国实用医药》2017年第7期126-128,共3页China Practical Medicine

摘　　要：目的研究肝硬化腹水合并低钠血症患者的临床治疗。方法 85例消化内科收治的肝硬化腹水合并低钠血症患者,随机分为研究组(43例)和对照组(42例)。研究组患者在此基础上严格控制入水量并限制钠盐的摄入,对照组患者给予正常含钠饮食,血清钠≤120 mmol/L者给予3%氯化钠溶液静脉滴注治疗3~7 d,血清钠120~130 mmol/L者给予口服氯化钠溶液2次/d。对两组患者均给予2周的常规治疗,治疗后观察两组患者的临床疗效和肝性脑病、肝肾综合征及消化道出血等相关并发症发生情况。结果研究组患者的治疗总有效率为95.35%,明显高于对照组73.81%,差异具有统计学意义(P<0.05);研究组患者肝性脑病(4.65%)、肝肾综合征(2.33%)及消化道出血(23.26%)均低于对照组(26.19%、16.67%和52.38%),差异均具具有统计学意义(P<0.05)。结论对于肝硬化腹水患者在临床治疗过程中应该加强病情的监测,避免患者发生低钠血症,对于肝硬化腹水合并低钠血症的患者应在控制原发病的基础上,积极应用钠盐治疗,纠正低钠血症,促进患者疾病康复。Objective To study the clinical treatment of cirrhotic ascites complicated with hyponatremia patients. Methods A total of 85 cirrhotic ascites complicated with hyponatremia patients accepted in digestive internal medicine department were randomly divided into research group （43 cases） and control group （42 cases）. The research group received strict control intake of water and sodium, and the control group received normal sodium diet, with serum sodium ≤ 120 mmol/L patients for 3% sodium chloride solution by intravenous drip for 3～7 d, and serum sodium 120～130 mmol/L patients for oral sodium chloride solution for 2 times/d. Both groups received conventional treatment for 2 weeks, and observation were made on clinical curative effect, incidence of related complications of hepatic encephalopathy, hepatorenal syndrome and gastrointestinal bleeding after treatment in two groups. Results The research group had obviously higher total treatment effective rate as 95.35% than 73.81% in the control group, and the difference had statistical significance （P〈0.05）. The research group had lower incidence of hepatic encephalopathy （4.65%）, hepatorenal syndrome （2.33%） and gastrointestinal bleeding （23.26%） than the control group （26.19%, 16.67% and 52.38%）, and their difference had statistical significance （P〈0.05）. Conclusion For patients with cirrhosis ascites, disease monitoring should be strengthened in the process of clinical treatment, to avoid occurrence of hyponatremia, and for cirrhosis ascites complicated with hyponatremia patients, application of sodium treatment should be used actively on the basis of controlling primary disease, along with correction of hyponatremia, so as to promote disease rehabilitation in patients.

关 键 词：肝硬化腹水 低钠血症 临床治疗 

分 类 号：R575.2[医药卫生—消化系统]